Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00307177 · ClinicalTrials.gov registry record · Phase 2
Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT00307177 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 28 participants.
The verdict
NCT00307177, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this research is to compare reactions and antibody responses following receipt of different doses of the experimental influenza vaccine or standard influenza vaccine.
Interventions
- BIOLOGICAL Trivalent inactivated influenza vaccine
- BIOLOGICAL Trivalent Baculovirus-expressed Influenza HA vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2004-08 |
| Est. Completion | 2005-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00307177
The ClinicalTrials.gov registry entry for NCT00307177 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Trivalent inactivated influenza vaccine is the first listed.
NCT00307177 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00307177 about?
NCT00307177 is a clinical study titled "Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma". The purpose of this research is to compare reactions and antibody responses following receipt of different doses of the experimental influenza vaccine or standard influenza vaccine.
What is the current status of trial NCT00307177?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2004-08. Estimated completion is 2005-04.
What interventions are being tested in trial NCT00307177?
The interventions under investigation include: Trivalent inactivated influenza vaccine (BIOLOGICAL), Trivalent Baculovirus-expressed Influenza HA vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00307177?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.